Literature DB >> 25394853

Burden of Illness in Hereditary Angioedema: A Conceptual Model.

Anette Bygum1, Emel Aygören-Pürsün, Kathleen Beusterien, Emily Hautamaki, Zlatko Sisic, Suzanne Wait, Henrik B Boysen, Teresa Caballero.   

Abstract

The objective of the Hereditary Angioedema Burden of Illness Study in Europe was to assess the real-world experience of hereditary angioedema (HAE) from the patient perspective. Based on open-ended qualitative interviews with 30 patients from Spain, Germany and Denmark, 5 key themes emerged characterizing the impact of HAE on health-related quality of life (HRQoL): (i) unnecessary treatments and procedures, (ii) symptom triggers, (iii) attack impacts, (iv) caregiver impacts, and (v) long-term impacts. Patients for example experience unnecessary medical procedures due to diagnostic delays; anxiety and fear about attacks, and passing HAE to children; reduced work/school productivity; and limited career/educational achievement. Patient caregivers also experience worry and work/activity interruption during the attacks. In conclusion, a conceptual model was developed illustrating the hypothesized relationships among the wide-ranging short- and long-term HRQoL impacts of HAE. These findings can be used to highlight important issues in clinical management, raise awareness of the patients' experience among policymakers and help guide measurement of HRQoL outcomes in future studies in HAE.

Entities:  

Mesh:

Year:  2015        PMID: 25394853     DOI: 10.2340/00015555-2014

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  25 in total

1.  Assessing the cost and quality-of-life impact of on-demand-only medications for adults with hereditary angioedema.

Authors:  Anthony J Castaldo; Christian Jervelund; Deborah Corcoran; Henrik B Boysen; Sandra C Christiansen; Bruce L Zuraw
Journal:  Allergy Asthma Proc       Date:  2021-02-13       Impact factor: 2.587

Review 2.  The symptom experience of hereditary angioedema (HAE) patients beyond HAE attacks: literature review and clinician interviews.

Authors:  Milenka Jean-Baptiste; Robbin Itzler; Subhransu Prusty; Dylan Supina; Mona L Martin
Journal:  Orphanet J Rare Dis       Date:  2022-06-16       Impact factor: 4.303

Review 3.  The Humanistic, Societal, and Pharmaco-economic Burden of Angioedema.

Authors:  Hilary Longhurst; Anette Bygum
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

4.  Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study.

Authors:  William R Lumry; Karsten Weller; Markus Magerl; Aleena Banerji; Hilary J Longhurst; Marc A Riedl; Hannah B Lewis; Peng Lu; Giovanna Devercelli; Gagan Jain; Marcus Maurer
Journal:  Allergy       Date:  2020-12-24       Impact factor: 13.146

5.  Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom.

Authors:  Hilary J Longhurst; John Dempster; Lorena Lorenzo; Matthew Buckland; Sofia Grigoriadou; Christine Symons; Claire Bethune; Vincent Fabien; Catherine Bangs; Tomaz Garcez
Journal:  Allergy Asthma Clin Immunol       Date:  2018-08-06       Impact factor: 3.406

6.  Hereditary angioedema: the challenges of cross-border family investigation and treatment.

Authors:  Anna Trier Heiberg Brix; Trine Mehlbye Svensson; Malin Sandberg; Anette Bygum
Journal:  BMJ Case Rep       Date:  2020-04-14

7.  High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study.

Authors:  Veronica Squeglia; Alessandro Barbarino; Maria Bova; Carmela Gravante; Angelica Petraroli; Giuseppe Spadaro; Massimo Triggiani; Arturo Genovese; Gianni Marone
Journal:  Orphanet J Rare Dis       Date:  2016-09-29       Impact factor: 4.123

8.  Estimation of EuroQol 5-Dimensions health status utility values in hereditary angioedema.

Authors:  Emel Aygören-Pürsün; Anette Bygum; Kathleen Beusterien; Emily Hautamaki; Zlatko Sisic; Henrik B Boysen; Teresa Caballero
Journal:  Patient Prefer Adherence       Date:  2016-09-06       Impact factor: 2.711

9.  Use of a C1 Inhibitor Concentrate in Adults ≥65 Years of Age with Hereditary Angioedema: Findings from the International Berinert® (C1-INH) Registry.

Authors:  Anette Bygum; Inmaculada Martinez-Saguer; Murat Bas; Jeffrey Rosch; Jonathan Edelman; Mikhail Rojavin; Debora Williams-Herman
Journal:  Drugs Aging       Date:  2016-11       Impact factor: 3.923

10.  Advances in Hereditary Angioedema: The Prevention of Angioedema Attacks With Subcutaneous C1-Inhibitor Replacement Therapy.

Authors:  William Lumry; Teri Templeton; Laurel Omert; Donald Levy
Journal:  J Infus Nurs       Date:  2020 May/Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.